Abstract
The postresectional tumor recurrence rate is high in patients with hepatocellular carcinoma (HCC). To improve the long-term outcome for HCC patients after potentially curative resection, effective measures in reducing the recurrence risk are mandatory. The aim of adjuvant therapy is to decrease the incidence, or delay tumor recurrence, or to prevent new tumor formation in the liver remnant after hepatic resection. Various therapeutic modalities, including transarterial chemoembolization, systemic and loco-regional chemotherapy, I-131-lipiodol transarterial infusion, immunotherapy and treatment with anti-angiogenesis agents have been evaluated in the adjuvant setting. A review of the current evidence of adjuvant therapy in HCC patients indicates that the role of adjuvant therapy after hepatic resection for HCC patients has not been well established. Further randomized controlled studies are needed to confirm efficacy of the adjuvant protocols.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
